Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.
January 2023 AbbVie Inc. Company Confidential
Polygenic score-adjusted PSA may improve screening accuracy in prostate cancer
June 2nd 2023“We showed that genetic correction of PSA levels has the potential to both reduce unnecessary biopsies and improve our ability to detect tumors with a more aggressive profile," says Linda Kachuri, PhD, MPH.
2 Clarke Drive
Cranbury, NJ 08512